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Dosage regime claims in the EPO – the G-02/08 Dosage regime/Abbott hearing 
 
On 5 November 2009 the EPO Enlarged Board of Appeal held its hearing on case G-2/08 
Dosage regime/Abbott. Abbott’s application1 for a Swiss type dosage regime claim to “the use 
of nicotinic acid ... for the manufacture of a sustained release medicament for use in the 
treatment by oral administration once per day prior to sleep, of hyperlipidaemia ...” had been 
rejected by the Examining Division. Upon appeal, Technical Board of Appeal 3.3.02, in 
interlocutory decision T-1319/04 Kos,2 had referred the following three questions to the 
Enlarged Board: 
1. Where it is already known to use a particular medicament to treat a particular illness, can 
this known medicament be patented under the provisions of Articles 53(c) and 54(5) 
EPC 2000 for use in a different, new and inventive treatment by therapy of the same 
illness? 
2. If the answer to question 1 is yes, is such patenting also possible where the only novel 
feature of the treatment is a new and inventive dosage regime? 
3. Are any special considerations applicable when interpreting and applying Articles 53(c) 
and 54(5) EPC 2000? 
 
Abbott and the President of the EPO were invited to make submissions and all other interested 
parties were given the opportunity to submit amicus briefs. Fifteen amicus briefs were submitted, 
inter alia by patent attorney associations, by pharmaceutical manufacturers and their associations 
and by a former member of the Enlarged Board. After setting the date for the hearing, the 
Enlarged Board advised Abbott and the EPO President, the only parties who would appear 
                                                 
1 The applicant, initially Kos Life Sciences Inc., has changed its name to Abbott Respiratory LLC. 
2 T-1319/04 Kos Life Sciences, Inc., Decision of the Technical Board of Appeal 3.3.02 of 22 April 2008, European 
Patent Office, Munich. Available at <https://register.epoline.org/espacenet/regviewer> under application number 
94306847 [last checked 8 November 2009]. 
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before the Board at the hearing, that discussion might be expected to focus on the following 
points: 
a) The meaning of the difference in language between question 1 and Art. 54(5) EPC; 
b) The identification of the change in the law brought about by the revision of EPC 19733 
to create EPC 20004; 
c) The consequences of that change, in particular in relation to Swiss type use claims and 
purpose-limited second indication product claims (so-called EPC 2000 claims);5 
d) The relevance of the prohibition, retained in EC 2000, on patenting methods of medical 
treatment; 
e) Whether there should be any difference in treatment between the cases where the dosage 
regime is characterised by the quantity of drug administered and where it is characterised 
by the activities involved in its administration; and 
f) A comparison between existing Enlarged Board decisions and decisions of the Technical 
Boards of Appeal relating to second or further non-medical uses. 
 
On the first of these points, at the hearing Abbott6 was of the view that the wording indicated 
that inventive step was not at issue in the present case, while the EPO President was of the 
opposite view, i.e. that inventive step was indeed at issue. 
 
                                                 
3 Convention on the grant of European patents (European Patent Convention), 12th Ed. (2006), European Patent 
Office, Munich. 
4 Convention on the grant of European patents (European Patent Convention), 13th Ed. (2007), European Patent 
Office, Munich. 
5 Swiss type claims are claims to a process for drug manufacture which derive their novelty from the purpose for 
which the drug is to be used, i.e. of the format “the use of compound X for the manufacture of a medicament for 
use in method of medical treatment Y”. EPC 2000 claims, a term that seems to have been coined by the Enlarged 
Board, are purpose-limited product claims of the format authorised by Art. 54(5) EPC 2000, i.e. of the format 
“Compound X for use in method of medical treatment Y”. 
6 References to statements by Abbott or the EPO President are of course to statements by their respective 
representatives at the hearing. 
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Asked to identify the change in the law brought about by the introduction of Art. 54(5) EPC 
2000, Abbott argued that there was no substantive change. Abbott identified “two critical 
sections of the travaux préparatoires”, cited in paragraphs 12 and 13 of the EPO President’s 
submissions7 of 28 January 2009 (citations respectively from the Swiss delegation’s proposal 
MR/18/008 and from paragraph 139 of the Minutes of the Munich Diplomatic Conference 
which decided the amendment to the EPC, MR/24/009). According to the passage quoted in 
paragraph 12, the clear intention of the legislator in introducing Art. 54(5) EPC was to enshrine 
the case law of the Enlarged Board of Appeal. This raised the question, according to Abbott, as 
to whether this meant only decision G-5/83 Eisai10 or also the Technical Board of Appeal case 
law that has evolved from that decision. In view of the statement in the travaux préparatoires, 
quoted in paragraph 13, that “the aim of the Basic Proposal was to keep the legal status quo”, for 
Abbott the conclusion had to be that the Technical Board case law should also be considered. In 
order to interpret the Eisai decision properly, Abbott submitted, it was necessary to look into the 
arguments against the type of claim Abbott was seeking in the present case, namely dosage 
regime claims. Abbott referred to the arguments put forward in the amicus brief11 filed by 
Ratiopharm (a generic manufacturer) as to the proper interpretation of Eisai and labelled 
Ratiopharm’s position as “very radical” because it argued that second medical uses should be 
understood as only referring to using known drugs to treat new illnesses. This would make the Swiss 
type claims of several granted patents invalid, such as claims characterised by the selection of 
                                                 
7 Letter dated 28 January 2009 from the President of the European Patent Office. Available at 
<https://register.epoline.org/espacenet/regviewer> under application number 94306847 [last checked 8 November 
2009].  
8 MR/18/00: Basic proposal - explanatory notes - Article 54(4) and Article 54(5) EPC, European Patent Office, 
Munich. Available at <https://register.epoline.org/espacenet/regviewer> under application number 94306847 [last 
checked 8 November 2009]. 
9 MR/24/00: Conference of the contracting states to revise the 1973 European Patent Convention: Munich, 20 to 
29 November 2000: Conference proceedings, European Patent Office, Munich. Available at 
<http://documents.epo.org/projects/babylon/eponet.nsf/0/fa8da239660827a4c12572810041373f/$file/conf_pro
ceed_mr0024_en.pdf> [last checked 8 November 2009]. 
10 G-5/83 Eisai Co., Ltd., Decision of the Enlarged Board of Appeal dated 5 December 1984 G 5/83, (1985) 
Official Journal of the European Patent Office 60.  
11 Letter dated 29 October 2008 from Ter Meer, Steinmeister & Partner GbR. Available at 
<https://register.epoline.org/espacenet/regviewer> under application number 94306847 [last checked 8 November 
2009]. 
5 
 
patient populations, by route of administration, or by the achievement of a new technical effect 
on the body. Such an interpretation was fundamentally wrong as, Abbott argued, the Eisai 
decision laid down that “second medical use” should be construed broadly and that the words 
“specific use” in Art. 54(5) EPC should therefore be understood to mean that claims to products 
should be allowed if limited to any novel specified use (in contrast to the more general restriction 
“for use in medicine” that is allowed under Art. 54(4) EPC for cases of first medical use). 
 
The EPO President also commented on the change effected by EPC 2000, first clarifying that 
the exclusion from patentability of methods for medical treatment was initially based on a legal 
fiction (i.e. that such methods are not industrially applicable), but that in EPC 2000 they are 
simply listed with the other categories excluded from patentability. This exclusion, the EPO 
President emphasised, was based on ethical and social grounds. Nonetheless, Art. 53(c) EPC 
2000, the current location of this exclusion, should be construed in exactly the same way as its 
predecessor Art. 52(4) EPC 1973. The President went on to explain that ‘Swiss type’ protection 
was not legally codified in EPC 1973 and that uncertainty existed in some Member States as to 
its validity. Meanwhile, however, this uncertainty had been eliminated by the introduction of Art. 
54(5) EPC, and even though the words “specific use” in Art. 54(5) EPC 2000 are not defined, 
specific use should be understood broadly, i.e. not as being limited to new illnesses. The EPO 
President stated that “it was the clear intention of the legislator to improve protection in this 
field”, upon which the Chairman of the Enlarged Board, Dr Messerli, asked the EPO President 
to explain in which sense this was so. The EPO President replied: “in the sense of removing the 
legal uncertainty”. 
 
The position of both Abbott and the EPO President on the effect of the introduction of Art. 
54(5) EPC was thus clear: for second and further medical uses, purpose-limited product claims 
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should be allowed and the new use need not be the treatment of a new disease but might be a 
new dosage regime for the treatment of the same disease. 
 
Turning to the consequences of the introduction of Art. 54(5) EPC, discussion point (c) above, 
Abbott stated that EPC 2000 was intended to maintain the status quo, albeit with a shift to a 
different claim format. Abbott stressed, however, that Swiss type claims must remain valid, as 
Eisai had not been overruled and as so many Swiss type claims had already been granted. 
Guidance from the Enlarged Board on the equivalence of Swiss type and EPC 2000 claims was 
urgently needed, however, not least because recently issued guidelines for EPO examiners state 
that the claim scope of both types of claims must be regarded as identical. 
 
The Chairman of the Enlarged Board asked Abbott whether in their view, the claim scope was 
identical. Abbott said yes. The Chairman then referred to the amicus brief12 of Julian Cockbain, 
and asked Abbott to consider an example given therein. The example relates to a known 
compound (compound X) which is found to be useful taken in one dosage (dosage Y) for 
treating disease A, then later found to be useful in the same dosage for treating disease B, then 
later still found to be more useful in a different dosage (dosage Z) for treating disease B. 
 
Cockbain had argued that under EPC 1973 the inventor of the application of compound X to 
treat disease A could obtain a patent to "compound X for use in medicine". The grant of such a 
patent leaves the freedom of action of the physician or pharmacist unaffected as the compound 
had previously not been available in medically approved form, so there was no generic to 
substitute with. After the patent expired, generic versions of compound X for the treatment of 
                                                 
12 Letter dated 21 May 2009 from Julian Cockbain. Available at <https://register.epoline.org/espacenet/regviewer> 
under application number 94306847 [last checked 8 November 2009]. 
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disease A could reach the market and be used legitimately. Also under EPC 1973, the inventor of 
the application of the compound to treat disease B could obtain a patent for "the use of 
compound X for the manufacture of a medicament for use in treatment of disease B". The 
physician treating disease B would then have a new drug in her arsenal and her position was 
clearly improved. A generic version of compound X might be available, but only from 
companies expressly advertising their product as for use in treating disease A. The physician or 
pharmacist would thus have the option to substitute without infringing (for, if the generic was 
manufactured for treating disease A and not disease B, the Swiss type claim would not be 
infringed by her actions). Under EPC 2000 however, Cockbain argued, the inventor of the first 
treatment of disease B with compound X could obtain a patent for "compound X for use in 
treating disease B", i.e. for a product as such rather than for a process for its manufacture. If the 
physician or pharmacist substituted generic compound X, she would be infringing such a claim. 
With the second disease B invention (using dosage Z to treat disease B), the question arose as to 
whether its inventor could obtain a patent with dosage regime claims to "the use of compound X 
for the manufacture of a medicament to be given in dosage Z in the treatment of disease B" or 
to "compound X for use in dosage Z for treating disease B". With the first of these claims, the 
Swiss type claim of EPC 1973, substitution by making up dosage Z using the generic available 
for disease B in dosage Y would neither infringe nor be seen to be risky. With the second claim, 
the product per se claim of EPC 2000, however, such substitution would infringe. Thus, with Swiss 
type claims, the physician cannot infringe by her use of any legitimately available medical supplies 
while, with EPC 2000 claims, the physician’s use of a legitimately available generic can infringe – 
a situation which does not occur with claims to new pharmaceuticals or to first indications since no generic 
equivalent can then legitimately be available on the physician’s shelves. 
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The Chairman asked Abbott whether a physician would indeed infringe under the EPC 2000 
claim format. Abbott noted that this had to do with infringement and hence fell under national 
law. On being pressed for an answer, Abbott stated that the amendment of the law implied no 
change as to whether the physician would infringe.  
 
The Chairman asked Abbott to explain why this was the case, to which Abbott replied that, 
under UK law, the physician would not infringe. The Chairman referred to Cockbain’s amicus 
brief again, repeating the example given and his earlier question as to whether a physician would 
infringe under the new EPC 2000 claim format. Abbott said they might have misunderstood the 
Chairman’s question, upon which the Chairman explained the example again and repeated his 
question again. Abbott indicated that they had now understood the question and repeated that 
this related to questions of infringement under national law, but that they would nevertheless 
attempt to give an answer. If the dosage form is novel, Abbott said, whether there is 
infringement will depend on the regulatory environment, more particularly on the surrounding 
circumstances of distribution and use of the drug. Abbott added that it was not helpful to think 
about this issue in terms of the physician. The Chairman replied that methods of medical 
treatment are excluded from patentability and that, although during the process leading up to the 
amendment of the EPC, attempts were made to delete this exclusion, it was maintained. He then 
once more repeated his question whether a physician would infringe claims in the EPC 2000 
format. Abbott repeated its reply that this regarded infringement and noted that there might be 
provisions in national laws to ensure freedom of operation for the physician. 
 
The Chairman then asked the EPO President to comment on the same question. The EPO 
President said that it was clear from EPC 2000 that the legislator had chosen the EPC 2000 
claim format, and at the same time to keep the legal status quo - this implied that the legislator 
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did not intend to introduce a broader scope of protection than that offered by Swiss type claims 
and so that the scope of protection of both claim formats was identical. It was added by the 
EPO President that in the future there was no need to maintain Swiss type claim protection, as 
the legislator had wanted to abolish this. As to Swiss type claims in existing granted patents, the 
EPO President considered that these should be replaced by EPC 2000 claims. 
 
The Chairman asked Abbott to consider a claim of the type “substance X manufactured for use 
in a method of treatment” and to explain who would infringe such a claim. Abbott said that they 
could not assist the Chairman with the question posed, as the claim type in question was a hybrid 
claim form which had elements of a Swiss type claim as well as being a product claim. As no case 
law existed on such claims, Abbott could not answer the Chairman’s question. 
 
Abbott subsequently noted, with regard to physicians’ freedom to operate, that it should not be 
forgotten that ‘first medical use’ claims also impact on the freedom of physicians, as they are also 
in danger of infringing such claims (rather than just being at risk of infringing second or further 
medical use claims). 
 
The Chairman asked Abbott whether it was the case that the remaining freedom of physicians is 
shrinking further and further. Abbott asked whether they could come back to that later. 
 
Enlarged Board member Dr Günzel then put a question to the EPO President: why, she asked, 
does the President say the claim scope of both types of claim is identical? The President replied 
that the travaux préparatoires showed that the claim scope must be considered to be identical 
because both types of claim derive their novelty from the new use. Moreover, the EPO President 
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added, instructions had been given to the EPO examiners that they must regard the claims as 
being identical in scope. 
 
Enlarged Board member Dr Schachenmann, addressing the EPO President, noted that the scope 
of patent protection is defined by the claims and that in the EPC 2000 claim there is no 
reference to “manufacture”. Therefore, he said, one could envisage a physician using a generic 
drug and thereby potentially infringing such an EPC 2000 claim. That is why it is crucial to bear 
in mind Art. 53(c) EPC, he explained. Also according to the UK Court of Appeal Actavis 
decision,13 he added, the manufacture aspect is decisive. He wanted to know what the President’s 
view on this issue was. The President did not give a reply. The Chairman then asked Abbott 
whether they would like to comment on the Actavis case. Abbott argued that, contrary to some 
of the assumptions made in some of the amicus briefs there was no inconsistency in the UK case 
law. However, Abbott did admit that in some EPC member states uncertainty exists as to the 
comparability of scope of Swiss type claims and EPC 2000 claims and that the guidance of the 
Enlarged Board was therefore needed. 
 
The Chairman asked Abbott: assuming that EPC 2000 claims would be accepted, what would 
remain of the physician’s freedom, or put differently: what would be left under Art. 53(c) EPC? 
In reply, Abbott provided two examples of what physicians would still be free to do: to take a 
patient’s blood pressure and to use surgical methods. Abbott contended that drug products are 
not methods of treatment and that the EPC 2000 claim format would not limit the freedom of 
operation of physicians. 
 
                                                 
13 Actavis UK Limited and Merck & Co Inc, [2008] EWCA Civ 444. 
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On the same topic, the EPO President stated that medical practice should not be hindered by 
patent law as public health must be guaranteed, and noted that when the EPC was revised in 
2000 the legislator explicitly refrained from deleting the exclusion from patentability of methods 
of treatment. However, according to the EPO President, Art. 53(c) EPC, last sentence (which 
allows drugs to be patented) already limits the freedom of physicians in order to encourage 
research and development of medicaments. Articles 54(4) and 54(5) EPC had to be seen as 
providing compensation for the exclusion from patentability of medical methods and the 
purpose of this compensation was to encourage R&D. In this regard the President endorsed the 
approach expressed in decision T-1020/03 Genentech.14 
 
Abbott expressed its agreement with the views of the President and referred to the principle that 
exceptions to patentability must be construed narrowly. Enlarged Board member Dr Günzel 
asked Abbott where such a principle could be found in the Vienna Convention on the Law of 
Treaties. Abbott replied that they did not know. The Chairman noted that, for the sake of 
consistency, if one advocates narrow construction for the purposes of Art. 53(c) EPC, one must 
also advocate narrow construction for the purposes of Articles 54(4) and 54(5) EPC, but that 
apparently the latter was not advocated by Abbott. 
 
The discussion then moved to Question 2 of the referral. Asked by the Chairman to make 
observations on Question 2, Abbott argued that there was no reason to treat claims characterised 
by dosage regime (i.e. dosage quantity or timing) differently, for they represented R&D 
expenditure which might deliver medical benefits. The EPC did not allow differentiation in the 
field of “specific uses”. Abbott argued that claims for new routes of administration of drugs 
provided an example of a category of second medical use claims which has been permitted by 
                                                 
14 T-1020/03 Genentech, Inc., Decision of Technical Board of Appeal 3.3.04 dated 29 October 2004, (2007) 
Official Journal of the European Patent Office 204-257. 
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the EPO and which lay closer to what physicians do in the clinic than do dosage regime claims. 
In Abbott’s view, there was no way to draw a line between dosage regimes and other second 
medical uses and, moreover, there is no basis in the EPC to draw a line. In this regard they too 
endorsed decision T-1020/03 Genentech. Thus, Abbott concluded, it was much simpler not to 
draw a line and to allow claims to all kinds of second medical uses. 
 
On the same topic, the EPO President began by referring to paragraph 20 of decision G-5/83 
Eisai: “Where the medicament itself is novel ... the ordinary requirements of Article 54(1) to (4) 
EPC will be met and there will in principle be no difficulty over the question of novelty, whether 
the claim be directed to the medicament per se or to the use of the active ingredient to prepare 
the medicament. The critical case is, however, that in which the medicament resulting from the 
claimed use is not in any way different from a known medicament.” The EPO President added 
that the role of the physician was not limited to the administration of medicaments, but also 
included the selection of the medicament and, therefore, it was not justified to distinguish 
between these types of activities. Moreover, according to the President, a physician would almost 
never say “take 5mg of this drug prior to sleep”, so there was no reason to single out dosage 
regimes. Abbott expressed its agreement with this view. 
 
The Chairman asked Abbott whether in order for patentability there has to be a functional 
technical feature. Enlarged Board member Dr Schachenmann joined the Chairman in asking this 
question and, with reference to decision G-2/88 Mobil,15 asked Abbott what ought to be the 
nature of the “specific use” of Art. 54(5) EPC in order to achieve patentability.  Abbott replied 
that it was better to deal with this issue under the heading of inventive step rather than novelty. 
They appreciated the reference to the Mobil decision, but noted that Mobil concerned non-medical 
                                                 
15 G-2/88 Friction reducing additive/MOBIL III, (1985) Official Journal of the European Patent Office 64. 
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second use claims, claims which, unlike medical second use claims, do not get special treatment by 
the legislator.  
 
Before closing the hearing and announcing that a decision would be issued in writing, the 
Chairman obtained Abbott’s confirmation that the answers to the questions before the Enlarged 
Board should, in Abbott’s opinion, be yes, yes and no.  
 
The written decision is awaited with great interest. 
 
